Compare News Corporation Class A Common Stock (NWSA) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
News Corporation Class A Common Stock vs Repligen Corporation Common Stock — how do they compare? News Corporation Class A Common Stock trades at $29.49 (market cap $16.49B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: News Corporation Class A Common Stock is the larger of the two by market cap, and News Corporation Class A Common Stock pays a 0.67% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold News Corporation Class A Common Stock for 6 Days and Repligen Corporation Common Stock for 0 Days on average.
| NWSA | RGEN | |
|---|---|---|
Market Cap | $16.49B | $11.14B |
Volume | 2,643,378 | 1,259,263 |
Sector | Media | Health |
52-Week High | $31.19 | $194.57 |
52-Week Low | $22.40 | $102.87 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $17.31B | $11.02B |
Dividend Yield | 0.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
News Corporation (NWSA) trades at $29.63, up 0.85% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $32.20. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.35 surpassing the $0.21 expectation. Revenue for 2025 reached $8.45 billion, though net income is projected to decline significantly in 2026. Recent news highlights include the launch of a personalized news AI, 'Hamilton,' and ongoing speculation about a potential re-merger with Fox Corp.
The outlook is cautiously optimistic, supported by strong analyst sentiment and consistent earnings beats. Key opportunities lie in digital real estate and news monetization, while risks include a projected profit margin contraction and broader market volatility. The stock's current valuation, with a P/E of 28.77, suggests growth expectations are already priced in, requiring sustained execution to justify further upside.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About News Corporation Class A Common Stock
News Corporation operates businesses in news and information services, digital real estate, and book publishing. Its brands include Dow Jones, The Wall Street Journal, HarperCollins, Realtor.com, and realestate.com.au.
Read more on NWSA →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
